1 Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68, 394-424, doi:10.3322/caac.21492 (2018).
2 Lee, A. W. et al. Evolution of treatment for nasopharyngeal cancer--success and setback in the intensity-modulated radiotherapy era. Radiother Oncol 110, 377-384, doi:10.1016/j.radonc.2014.02.003 (2014).
3 Sun, X. et al. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol 110, 398-403, doi:10.1016/j.radonc.2013.10.020 (2014).
4 Li, Y. et al. Induction Chemotherapy Plus Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma in Children and Adolescents: A Matched Cohort Analysis. Cancer Res Treat 50, 1304-1315, doi:10.4143/crt.2017.463 (2018).
5 Dawid, I. B., Breen, J. J. & Toyama, R. LIM domains: multiple roles as adapters and functional modifiers in protein interactions. Trends Genet 14, 156-162, doi:10.1016/s0168-9525(98)01424-3 (1998).
6 Hobert, O. & Westphal, H. Functions of LIM-homeobox genes. Trends Genet 16, 75-83, doi:10.1016/s0168-9525(99)01883-1 (2000).
7 Dawid, I. B., Toyama, R. & Taira, M. LIM domain proteins. C R Acad Sci III 318, 295-306 (1995).
8 Xu, Y. et al. LH-2: a LIM/homeodomain gene expressed in developing lymphocytes and neural cells. Proc Natl Acad Sci U S A 90, 227-231, doi:10.1073/pnas.90.1.227 (1993).
9 Tetreault, N., Champagne, M. P. & Bernier, G. The LIM homeobox transcription factor Lhx2 is required to specify the retina field and synergistically cooperates with Pax6 for Six6 trans-activation. Dev Biol 327, 541-550, doi:10.1016/j.ydbio.2008.12.022 (2009).
10 Tornqvist, G., Sandberg, A., Hagglund, A. C. & Carlsson, L. Cyclic expression of lhx2 regulates hair formation. PLoS Genet 6, e1000904, doi:10.1371/journal.pgen.1000904 (2010).
11 Hirota, J. & Mombaerts, P. The LIM-homeodomain protein Lhx2 is required for complete development of mouse olfactory sensory neurons. Proc Natl Acad Sci U S A 101, 8751-8755, doi:10.1073/pnas.0400940101 (2004).
12 Kim, J. H. et al. Lhx2 regulates bone remodeling in mice by modulating RANKL signaling in osteoclasts. Cell Death Differ 21, 1613-1621, doi:10.1038/cdd.2014.71 (2014).
13 Wu, H. K. et al. Identification of a human LIM-Hox gene, hLH-2, aberrantly expressed in chronic myelogenous leukaemia and located on 9q33-34.1. Oncogene 12, 1205-1212 (1996).
14 Shi, X. et al. miR-1238 inhibits cell proliferation by targeting LHX2 in non-small cell lung cancer. Oncotarget 6, 19043-19054, doi:10.18632/oncotarget.4232 (2015).
15 Gorantla, B., Asuthkar, S., Rao, J. S., Patel, J. & Gondi, C. S. Suppression of the uPAR-uPA system retards angiogenesis, invasion, and in vivo tumor development in pancreatic cancer cells. Mol Cancer Res 9, 377-389, doi:10.1158/1541-7786.MCR-10-0452 (2011).
16 Bouleau, S. et al. FGF1 inhibits p53-dependent apoptosis and cell cycle arrest via an intracrine pathway. Oncogene 24, 7839-7849, doi:10.1038/sj.onc.1208932 (2005).
17 Liu, P. et al. FGF1 and IGF1-conditioned 3D culture system promoted the amplification and cancer stemness of lung cancer cells. Biomaterials 149, 63-76, doi:10.1016/j.biomaterials.2017.09.030 (2017).
18 Ornitz, D. M. & Itoh, N. Fibroblast growth factors. Genome Biol 2, REVIEWS3005, doi:10.1186/gb-2001-2-3-reviews3005 (2001).
19 Zhang, L., Kharbanda, S., McLeskey, S. W. & Kern, F. G. Overexpression of fibroblast growth factor 1 in MCF-7 breast cancer cells facilitates tumor cell dissemination but does not support the development of macrometastases in the lungs or lymph nodes. Cancer Res 59, 5023-5029 (1999).
20 Kin, M. et al. Basic fibroblast growth factor regulates proliferation and motility of human hepatoma cells by an autocrine mechanism. J Hepatol 27, 677-687, doi:10.1016/s0168-8278(97)80085-2 (1997).
21 Tomlinson, D. C., L'Hote, C. G., Kennedy, W., Pitt, E. & Knowles, M. A. Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines. Cancer Res 65, 10441-10449, doi:10.1158/0008-5472.CAN-05-1718 (2005).
22 King, M. L. et al. WNT7A/beta-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer. Oncogene 34, 3452-3462, doi:10.1038/onc.2014.277 (2015).
23 El-Hariry, I., Pignatelli, M. & Lemoine, N. R. FGF-1 and FGF-2 regulate the expression of E-cadherin and catenins in pancreatic adenocarcinoma. Int J Cancer 94, 652-661, doi:10.1002/ijc.1515 (2001).
24 Powers, C. J., McLeskey, S. W. & Wellstein, A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 7, 165-197 (2000).
25 Imamura, T. et al. Recovery of mitogenic activity of a growth factor mutant with a nuclear translocation sequence. Science 249, 1567-1570, doi:10.1126/science.1699274 (1990).
26 Dignass, A. U., Tsunekawa, S. & Podolsky, D. K. Fibroblast growth factors modulate intestinal epithelial cell growth and migration. Gastroenterology 106, 1254-1262, doi:10.1016/0016-5085(94)90017-5 (1994).
27 Shi, H. et al. The FGF-1-specific single-chain antibody scFv1C9 effectively inhibits breast cancer tumour growth and metastasis. J Cell Mol Med 18, 2061-2070, doi:10.1111/jcmm.12371 (2014).
28 Turner, N. & Grose, R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10, 116-129, doi:10.1038/nrc2780 (2010).
29 Bohrer, L. R. et al. Activation of the FGFR-STAT3 pathway in breast cancer cells induces a hyaluronan-rich microenvironment that licenses tumor formation. Cancer Res 74, 374-386, doi:10.1158/0008-5472.CAN-13-2469 (2014).
30 Pastushenko, I. & Blanpain, C. EMT Transition States during Tumor Progression and Metastasis. Trends Cell Biol 29, 212-226, doi:10.1016/j.tcb.2018.12.001 (2019).
31 Pinto do, O. P., Richter, K. & Carlsson, L. Hematopoietic progenitor/stem cells immortalized by Lhx2 generate functional hematopoietic cells in vivo. Blood 99, 3939-3946, doi:10.1182/blood.v99.11.3939 (2002).
32 Porter, F. D. et al. Lhx2, a LIM homeobox gene, is required for eye, forebrain, and definitive erythrocyte development. Development 124, 2935-2944 (1997).
33 Kuzmanov, A. et al. LIM-homeobox gene 2 promotes tumor growth and metastasis by inducing autocrine and paracrine PDGF-B signaling. Mol Oncol 8, 401-416, doi:10.1016/j.molonc.2013.12.009 (2014).
34 Polyak, K. & Weinberg, R. A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9, 265-273, doi:10.1038/nrc2620 (2009).
35 Chang, Y. W. et al. Diverse Targets of beta-Catenin during the Epithelial-Mesenchymal Transition Define Cancer Stem Cells and Predict Disease Relapse. Cancer Res 75, 3398-3410, doi:10.1158/0008-5472.CAN-14-3265 (2015).
36 Sanchez-Tillo, E. et al. beta-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc Natl Acad Sci U S A 108, 19204-19209, doi:10.1073/pnas.1108977108 (2011).
37 MacDonald, B. T., Tamai, K. & He, X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 17, 9-26, doi:10.1016/j.devcel.2009.06.016 (2009).
38 Jensen, J., Brennesvik, E. O., Lai, Y. C. & Shepherd, P. R. GSK-3beta regulation in skeletal muscles by adrenaline and insulin: evidence that PKA and PKB regulate different pools of GSK-3. Cell Signal 19, 204-210, doi:10.1016/j.cellsig.2006.06.006 (2007).
39 Sutherland, C., Leighton, I. A. & Cohen, P. Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem J 296 ( Pt 1), 15-19, doi:10.1042/bj2960015 (1993).